R*2 and the apparent concentration of FMX in the tumor (FMXC) are considered biomarkers of liposomal irinotecan (nal-IRI) drug uptake into that tumor lesion, which in turn would determine response of that tumor to nal-IRI. Historically, quantification of R*2 and FMXC had been implemented by using a calibration phantom and acquiring patient scans both pre-FMX and post-FMX. Here we have demonstrated a pre-treatment FMX-enhanced MRI companion biomarker of response to nal-IRI in mBC patients that can be computed from a single16-24 h post-FMX MRI scan without the need for calibration phantoms or pre-FMX scans.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords